Skip to main content
. 2023 Feb 20;24(4):4176. doi: 10.3390/ijms24044176

Figure 3.

Figure 3

When anti-EGFR nanobodies reach the surface of cancer cells, anti-EGFR nanobodies can compete with EGF to bind EGFR dimers, target cancer cells and inactivate intracellular receptor tyrosine kinase (RTK) signaling pathway, causing cascade reactions of downstream pathways, thereby inhibiting the proliferation of cancer cells (This figure was created with BioRender.com, accessed on 8 August 2022).